Intravitreous Bevacizumab as Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic Study

Open Access

11 August 2008

journal article
research article
Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)

Vol. 126 (8) , 1161-1163
https://doi.org/10.1001/archophthalmol.2008.1

Abstract

Overexpression of vascular endothelial growth factor (VEGF) appears important in the pathogenesis of retinopathy of prematurity (ROP). Bevacizumab (Avastin; Genentech, Inc, South San Francisco, California) is a recombinant humanized monoclonal IgG1 antibody. It binds to and inhibits the biological activity of human VEGF.¹ It has been estimated that more than 10 000 patients worldwide have been treated with intravitreous bevacizumab.² We report results of a study in postmortem eyes with intravitreous bevacizumab treatment for zone 1, stage 2+ ROP in an extremely low-birth-weight infant.

Keywords

This publication has 5 references indexed in Scilit:

Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury
The American Journal of Pathology, 2007
Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twenty-Four–Week Results of an Uncontrolled Open-Label Clinical Study
Yearbook of Ophthalmology, 2007
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide
British Journal of Ophthalmology, 2006
Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve
Genes & Development, 2004
Vascular Endothelial Growth Factor Has Neurotrophic Activity and Stimulates Axonal Outgrowth, Enhancing Cell Survival and Schwann Cell Proliferation in the Peripheral Nervous System
Journal of Neuroscience, 1999